BridgeBio Pharma, Inc. Cash and Restricted Cash
BridgeBio Pharma, Inc. (BBIO) had Cash and Restricted Cash of $680.04 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-10
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $680.04M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $882.02M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $572.14M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $645.10M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $680.04M 10-Q · filed 2026-08-10 |
| 2026-03-31 | $882.02M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $572.14M 10-K · filed 2026-02-24 |
| 2025-09-30 | $645.10M 10-Q · filed 2025-10-29 |
| 2025-06-30 | $751.10M 10-Q · filed 2026-08-10 |
| 2025-03-31 | $542.74M 10-Q · filed 2026-05-07 |
| 2024-12-31 | $683.24M 10-K · filed 2026-02-24 |
| 2024-09-30 | $407.88M 10-Q · filed 2025-10-29 |
| 2024-06-30 | $549.51M 10-Q · filed 2025-08-05 |
| 2024-03-31 | $477.50M 10-Q · filed 2025-04-29 |
| 2023-12-31 | $394.73M 10-K · filed 2026-02-24 |
| 2023-09-30 | $524.14M 10-Q · filed 2024-11-12 |
| 2023-06-30 | $324.64M 10-Q · filed 2024-08-01 |
| 2023-03-31 | $435.11M 10-Q · filed 2024-05-02 |
| 2022-12-31 | $416.88M 10-K · filed 2025-02-20 |
| 2022-09-30 | $485.79M 10-Q · filed 2023-11-02 |
| 2022-06-30 | $472.65M 10-Q · filed 2023-08-03 |
| 2022-03-31 | $374.19M 10-Q · filed 2023-05-04 |
| 2021-12-31 | $396.37M 10-K · filed 2024-02-22 |
| 2021-09-30 | $183.08M 10-Q · filed 2022-11-03 |
| 2021-06-30 | $381.13M 10-Q · filed 2022-08-04 |
| 2021-03-31 | $473.77M 10-Q · filed 2022-05-05 |
| 2020-12-31 | $358.68M 10-K · filed 2023-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |